Rising Star Clinical Diagnostic Tool Category
Eyenuk has been named a finalist in the Rising Star Clinical Diagnostic Tool category of the UCSF Digital Health Awards. Produced by the University of California at San Francisco’s UCSF Health Hub, Eyenuk was among over 1,500 disruptive companies from across the globe that entered 11 categories of this prestigious awards program. Winners of the award will be announced at the HLTH 2022 conference in Las Vegas, November 13-16.
“It’s an honor to be named as a finalist for the Rising Star Clinical Diagnostics Tool category,” said Kaushal Solanki, Eyenuk’s CEO and Founder. “It’s the second time this week that Eyenuk achieved a major milestone, validating our company’s mission to use AI technology to detect preventable, vision-threatening eye diseases which has been more than a decade in the making.”
The company announced on Monday that it secured a $26 million Series A financing round and will use the capital to expand its AI product platform with additional disease indications and advanced care coordination, and to accelerate the platform’s global commercialization and adoption.
Eyenuk is leading the way in harnessing the power of AI to eliminate preventable blindness globally, through its versatile digital health platform that enables automated AI diagnosis and coordination of care. Eyenuk’s flagship EyeArt® AI system has been more broadly adopted worldwide than any other autonomous AI technology for ophthalmology.
Since achieving FDA clearance in 2020, the EyeArt system has been used in over 200 locations in 18 countries, including 14 U.S. states, to screen over 60,000 patients and counting. It is the first and only technology to be cleared by the FDA for autonomous detection of both referable and vision-threatening diabetic retinopathy without any eye care specialist involvement.
Last month a major peer-reviewed study published in Ophthalmology Science, a publication of the American Academy of Ophthalmology, found that the EyeArt AI system is far more sensitive in identifying referable diabetic retinopathy than dilated eye exams by ophthalmologists and retina specialists.
UCSF Health Hub isn’t the only major awarding organization to recognize Eyenuk for innovation. In June, Eyenuk won Juniper Research’s Future Digital Health award for the “Best Digital Diagnostics Solution” (link). Juniper Research’s Future Digital Health Innovation Awards are presented to companies that deliver imaginative, innovative products or services that have the potential to disrupt their ecosystems and provide significant benefits to their target audience.